VC
EPIX

Vivo Capital’s ESSA Pharma EPIX Stock Holding History

Vivo Capital’s Portfolio EPIX Stock Details EPIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-744,058
Closed -$10.6M – 55
2021
Q4 		$10.6M Sell
744,058
-312,009
-30% -$3.48M 0.64% 37
2021
Q3 		$8.45M Sell
1,056,067
-495,613
-32% -$7.88M 0.38% 43
2021
Q2 		$44.3M Sell
1,551,680
-517,227
-25% -$15M 1.92% 12
2021
Q1 		$60.1M Buy
2,068,907
+175,000
+9% +$4.07M 2.11% 12
2020
Q4 		$22.6M Buy
1,893,907
+377,042
+25% +$2.65M 1.01% 23
2020
Q3 		$10.5M Buy
+1,516,865
New +$10.3M 0.6% 39

Other funds holding EPIX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vivo Capital's EPIX Position: Q1 2022 in Review

Vivo Capital sold out of ESSA Pharma (EPIX) in Q1 2022, closing a stake of 744,058 shares — an estimated $10.6M sold.

Vivo Capital first reported a position in EPIX in Q3 2020 and held it in 6 quarters. The position peaked at $60.1M in Q1 2021. 70 funds tracked by Wall St. Rank hold EPIX as of Q1 2022.

  • Vivo Capital reported no remaining ESSA Pharma position as of Q1 2022 after selling out during the quarter.
  • Vivo Capital sold 744,058 ESSA Pharma shares in Q1 2022, an estimated $10.6M.
  • Vivo Capital first reported a position in ESSA Pharma in Q3 2020 and held it in 6 quarters.
  • Vivo Capital's ESSA Pharma position peaked at $60.1M in Q1 2021.
  • 70 funds tracked by Wall St. Rank held ESSA Pharma as of Q1 2022.

Based on Vivo Capital's 13F filing for Q1 2022, filed 13 May 2022.